JPS6234733B2 - - Google Patents
Info
- Publication number
- JPS6234733B2 JPS6234733B2 JP60152571A JP15257185A JPS6234733B2 JP S6234733 B2 JPS6234733 B2 JP S6234733B2 JP 60152571 A JP60152571 A JP 60152571A JP 15257185 A JP15257185 A JP 15257185A JP S6234733 B2 JPS6234733 B2 JP S6234733B2
- Authority
- JP
- Japan
- Prior art keywords
- warm
- rde
- composition
- development
- sepsis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241001465754 Metazoa Species 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 13
- 239000002158 endotoxin Substances 0.000 claims description 12
- 206010040047 Sepsis Diseases 0.000 claims description 11
- 208000001395 Acute radiation syndrome Diseases 0.000 claims description 7
- 206010068142 Radiation sickness syndrome Diseases 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 3
- 229930195729 fatty acid Natural products 0.000 claims description 3
- 239000000194 fatty acid Substances 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical class P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 claims description 2
- 239000002953 phosphate buffered saline Substances 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 11
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 230000005855 radiation Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- 241000588921 Enterobacteriaceae Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940047120 colony stimulating factors Drugs 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US630013 | 1984-07-12 | ||
| US06/630,013 US4629722A (en) | 1984-07-12 | 1984-07-12 | Method of inhibiting the onset of acute radiation syndrome |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6193123A JPS6193123A (ja) | 1986-05-12 |
| JPS6234733B2 true JPS6234733B2 (enExample) | 1987-07-28 |
Family
ID=24525404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60152571A Granted JPS6193123A (ja) | 1984-07-12 | 1985-07-12 | 急性放射線症候群および敗血症抑制用組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4629722A (enExample) |
| JP (1) | JPS6193123A (enExample) |
| KR (1) | KR880000191B1 (enExample) |
| AU (1) | AU556971B2 (enExample) |
| BE (1) | BE902875A (enExample) |
| CH (1) | CH665355A5 (enExample) |
| DE (2) | DE3546592C2 (enExample) |
| FR (1) | FR2567403A1 (enExample) |
| GB (1) | GB2161381B (enExample) |
| IL (1) | IL75789A (enExample) |
| IT (1) | IT1214671B (enExample) |
| NL (1) | NL8501995A (enExample) |
| NZ (1) | NZ212691A (enExample) |
| ZA (1) | ZA855243B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4866034A (en) * | 1982-05-26 | 1989-09-12 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
| US5354782A (en) * | 1991-01-17 | 1994-10-11 | Merrell Dow Pharmaceuticals Inc. | Polyamine phenols as radioprotective agents |
| US5530113A (en) * | 1991-10-11 | 1996-06-25 | Eisai Co., Ltd. | Anti-endotoxin compounds |
| AU660325B2 (en) * | 1991-10-11 | 1995-06-22 | Eisai Co. Ltd. | Anti-endotoxin compounds and related molecules and methods |
| US6218166B1 (en) | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
| KR101378872B1 (ko) | 2006-09-26 | 2014-04-11 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 합성 애주번트를 함유하는 백신 조성물 |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| SI2437753T1 (sl) | 2009-06-05 | 2016-12-30 | Infectious Disease Research Institute | Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo |
| AU2012243039B2 (en) | 2011-04-08 | 2017-07-13 | Immune Design Corp. | Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses |
| PT2850431T (pt) | 2012-05-16 | 2018-07-23 | Immune Design Corp | Vacinas para hsv-2 |
| EP3711768A1 (en) | 2013-04-18 | 2020-09-23 | Immune Design Corp. | Gla monotherapy for use in cancer treatment |
| US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
| IL295025A (en) * | 2014-09-16 | 2022-09-01 | Bioincept Llc | Preparations and methods for the treatment of acute radiation syndrome |
| EP3341739A4 (en) | 2015-08-28 | 2019-07-10 | BioIncept LLC | MUTATED PEPTIDES AND METHOD FOR TREATING SUBJECTS THEREWITH |
| EP3341006A4 (en) | 2015-08-28 | 2019-03-13 | BioIncept LLC | COMPOSITIONS AND METHODS FOR TREATING NERVE DAMAGE |
| KR101909660B1 (ko) * | 2017-07-06 | 2018-10-18 | 이보미 | 안경알 자판기 서비스 제공 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1188519A (en) * | 1966-10-27 | 1970-04-15 | Wellcome Found | Method for the Purification of Lipopolysaccharides |
| US4435386A (en) * | 1982-05-26 | 1984-03-06 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| US4436728A (en) * | 1982-05-26 | 1984-03-13 | Ribi Immunochem Research, Inc. | Refined detoxified endotoxin product |
| CA1225592A (en) * | 1983-08-26 | 1987-08-18 | Ribi Immunochem Research Inc. | Refined detoxified endotoxin |
-
1984
- 1984-07-12 US US06/630,013 patent/US4629722A/en not_active Expired - Lifetime
-
1985
- 1985-07-09 NZ NZ212691A patent/NZ212691A/en unknown
- 1985-07-10 AU AU44758/85A patent/AU556971B2/en not_active Ceased
- 1985-07-11 FR FR8510629A patent/FR2567403A1/fr not_active Withdrawn
- 1985-07-11 NL NL8501995A patent/NL8501995A/nl not_active Application Discontinuation
- 1985-07-11 GB GB08517545A patent/GB2161381B/en not_active Expired
- 1985-07-11 ZA ZA855243A patent/ZA855243B/xx unknown
- 1985-07-12 KR KR1019850004992A patent/KR880000191B1/ko not_active Expired
- 1985-07-12 JP JP60152571A patent/JPS6193123A/ja active Granted
- 1985-07-12 BE BE0/215338A patent/BE902875A/fr not_active IP Right Cessation
- 1985-07-12 CH CH3039/85A patent/CH665355A5/de not_active IP Right Cessation
- 1985-07-12 IT IT8548347A patent/IT1214671B/it active
- 1985-07-12 DE DE3546592A patent/DE3546592C2/de not_active Expired
- 1985-07-12 IL IL75789A patent/IL75789A/xx unknown
- 1985-07-12 DE DE19853524992 patent/DE3524992A1/de active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6193123A (ja) | 1986-05-12 |
| IT1214671B (it) | 1990-01-18 |
| GB8517545D0 (en) | 1985-08-14 |
| CH665355A5 (de) | 1988-05-13 |
| KR880000191B1 (ko) | 1988-03-12 |
| ZA855243B (en) | 1986-02-26 |
| FR2567403A1 (fr) | 1986-01-17 |
| BE902875A (fr) | 1985-11-04 |
| KR860000867A (ko) | 1986-02-20 |
| US4629722A (en) | 1986-12-16 |
| GB2161381A (en) | 1986-01-15 |
| NL8501995A (nl) | 1986-02-03 |
| DE3524992A1 (de) | 1986-01-16 |
| AU4475885A (en) | 1986-01-16 |
| IL75789A0 (en) | 1985-11-29 |
| IT8548347A0 (it) | 1985-07-12 |
| DE3546592C2 (enExample) | 1988-06-01 |
| DE3524992C2 (enExample) | 1988-05-11 |
| NZ212691A (en) | 1988-02-12 |
| GB2161381B (en) | 1988-01-13 |
| AU556971B2 (en) | 1986-11-27 |
| IL75789A (en) | 1990-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pinkel | Actinomycin D in childhood cancer: A preliminary report | |
| JPS6193123A (ja) | 急性放射線症候群および敗血症抑制用組成物 | |
| CA2176298C (en) | A single high dose fluoroquinolone treatment | |
| Greco et al. | Treatment of oat cell carcinoma of the lung: complete remissions, acceptable complications, and improved survival. | |
| Aisner et al. | Chemotherapy versus chemoimmunotherapy for small‐cell undifferentiated carcinoma of the lung | |
| Picco et al. | Primary hypothyroidism as a consequence of 131‐I‐metaiodobenzylguanidine treatment for children with neuroblastoma | |
| WO1991002529A2 (en) | Product and method for killing abnormal vertebrate cells | |
| US4590060A (en) | Agent facilitating liposome cellular wall transport, a method for the production thereof and its use | |
| JPS6136221A (ja) | 免疫抑制剤としてのリコリンの使用 | |
| US2761807A (en) | Glycocyamine and methylating agent in vivo creatine producing composition | |
| DE3786456T2 (de) | Kombinationen von nekrose-tumor-faktoren und entzündungshemmenden mitteln für die behandlung von bösartigen und nicht bösartigen erkrankungen. | |
| EP0563127B1 (en) | Improved treatment method for cancer | |
| US5491150A (en) | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome | |
| US3560612A (en) | Method of alleviating hypercitricemia | |
| US3317381A (en) | Method for treating peptic ulcer | |
| DE69124380T2 (de) | Verfahren und zusammensetzungen für die behandlung durch t-zellen vermittelter krankheiten | |
| JP5553306B2 (ja) | 放射線障害防護剤 | |
| CN114081880A (zh) | 木香内酯及其衍生物在制备预防和/或治疗肠损伤的药物中的用途 | |
| CN110664817A (zh) | 铁调素拮抗剂ldn193189及其衍生物在制备药物中的应用 | |
| Newman et al. | Small cell lung carcinoma. A phase II evaluation of r‐interferon‐γ | |
| RU2188644C2 (ru) | Способ лечения туберкулеза легких | |
| US5641519A (en) | Method of treating endotoxic shock employing gallium compounds | |
| US4302452A (en) | Use of derivatives of 6α-methylprednisolone as an antiemetic | |
| Srinivasan et al. | High-dose antibiotic therapy is superior to a 3-drug combination of prostanoids and lipid A derivative in protecting irradiated canines | |
| Ward | Central nervous system tumors of childhood treated with CCNU, vincristine, and radiation |